★★★★★
Glaucoma
★★★★★
Essential Tremors
★★★★★
If those three supplements don't pan out for you or they help, but not enough, you might consider the addition of Citicoline for Essential Tremor (ET) as described in the study link below, which was beneficial for people with ET :
http://rmsjournal.org/Articles/635925245011741851.pdf
Here is a relevant quote from the study:
' Citicoline significantly improved essential tremor in this small group of subjects. '
Two caveats that I see to this study is the small size group and the fact that the equivalent oral dose used(400 mg/day), is significantly lower than other studies that have used Citicoline at 1000 mg or more per day for other health issues.
Art
Glaucoma
★★★★★
Here is a new study( March 2022) showing the efficacy of Citicoline at just 250 mg/day for Glaucoma :
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907038/
Here is a relevant quote from the study :
>>> ' With oral citicoline treatment, the loss in the average RNFL is prevented in POAG patients in the short-term. Study data show that citicoline may have a significant impact on slowing glaucoma progression, which could have a potential neuroprotective effect.'<<<
In the following RCT (June 2020) it is shown that even eye drops utilizing Citicoline is effective for Glaucoma :
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337116/
Here is a relevant quote from the study :
>>> ' Additional treatment with citicoline eyedrops to IOP-lowering treatment might reduce disease progression in patients with progressing glaucoma despite IOP ≤18 mm Hg. ' <<<
In this last comprehensive review (March 2021) the protective role of Citicoline against the effects of glaucoma related neurodegeneration are elucidated in greater detail :
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003774/
Here is a relevant quote from the study :
>>> ' In addition to the evidences of an improvement of psychophysical, morphological, and electrophysiological outcomes, coming from small comparative randomized pilot clinical trials or larger not controlled before-after studies (performed in different ophthalmological neurodegenerative diseases, like OAG, AION, and DR), for the first time a reduction of the rate of visual field progression has been recently reported in OAG patients in a large randomized double-masked placebo-controlled clinical trial, thus further supporting the clinical use of citicoline. ' <<<
:::::::::::::::::::::::::::::::::::::
Art
Glaucoma
★★★★☆
